ACON.NASDAQAclarion, INC
10-Q: Aclarion Inc. Reports Second Quarter 2024 Results Amidst Financial Restructuring
Sentiment:
Quarterly Report
Aclarion Inc. reports a net loss of $3.6 million for the first half of 2024, alongside a decrease in revenue and ongoing efforts to address financial challenges.
Capital raiseThe company completed a public offering in February 2024, raising approximately $3 million.The company secured additional funding through an equity line agreement, raising $1.75 million in the first half of 2024.The company will need to raise additional funds to continue funding its technology development.
Worse than expectedThe company's revenue decreased by 50% compared to the same period last year.The company's net loss increased from $2.6 million to $3.6 million year-over-year.The company's interest expense increased significantly due to increased debt.
Summary
- Aclarion Inc. reported a net loss of $3.6 million for the six months ended June 30, 2024, compared to a net loss of $2.6 million for the same period in 2023.
- The company's revenue decreased by 50% to $21,085 for the first half of 2024, down from $42,542 in the first half of 2023, primarily due to the conclusion of certain clinical activities.
- Operating expenses totaled $2.39 million for the first half of 2024, a decrease of $204,069 compared to the same period in 2023.
- The company experienced a significant increase in interest expense, reaching $463,672 for the first half of 2024, due to increased debt.
- Aclarion completed a public offering in February 2024, raising approximately $3 million, and secured additional funding through an equity line agreement.
- The company's cash balance was $1.18 million as of June 30, 2024, and management believes this will fund operations into the third quarter of 2024.
- There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
Sentiment
Score: 3
Explanation: The document indicates significant financial challenges, including a substantial net loss, declining revenue, and a going concern warning. While the company has raised capital, the overall outlook is negative due to the financial performance and operational risks.
Positives
- Operating expenses decreased by $204,069 for the first half of 2024 compared to the same period in 2023.
- The company successfully completed a public offering in February 2024, raising approximately $3 million.
- Aclarion secured additional funding through an equity line agreement, raising $1.75 million in the first half of 2024.
- The company made progress in reducing its debt through exchange agreements and cash payments.
Negatives
- The company experienced a net loss of $3.6 million for the first half of 2024, an increase from $2.6 million in the same period of 2023.
- Revenue decreased by 50% to $21,085 for the first half of 2024.
- Interest expense increased significantly to $463,672 for the first half of 2024.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share.
- The company's internal controls over financial reporting were deemed ineffective.
Risks
- The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional financing.
- Aclarion is subject to risks and uncertainties frequently encountered by companies in the early stages of development, including competition and limited access to additional funds.
- The company's ability to maintain its Nasdaq listing is at risk due to not meeting the minimum bid price requirement.
- The company's internal controls over financial reporting were deemed ineffective, which could lead to material misstatements in financial reporting.
- The company's revenue is highly dependent on clinical activity at customer sites, which can fluctuate.
Future Outlook
The company believes that the net proceeds from the February 2024 initial public offering and subsequent funding from the April 2024 equity line agreement will be sufficient to fund current operating plans into the third quarter of 2024. However, the company will need to raise additional funds to continue funding its technology development.
Management Comments
- Management plans to secure additional funding to continue technology development.
- Management is working to improve internal controls over financial reporting.
Industry Context
The company operates in the healthcare technology sector, leveraging magnetic resonance spectroscopy (MRS) and a proprietary biomarker to optimize clinical treatments. The company's financial performance is impacted by the pace of clinical activity at customer sites and the need for ongoing funding to support technology development.
Comparison to Industry Standards
- Aclarion's revenue decline of 50% is significant and indicates challenges in commercializing its technology compared to industry peers.
- The increase in net loss and interest expense suggests that the company is facing financial difficulties, which is not uncommon for early-stage medical technology companies.
- The company's reliance on external funding and the going concern warning are typical for companies in this sector that are still in the development and pre-revenue phase.
- Compared to companies like Butterfly Network (BFLY) or Nano-X Imaging (NNOX), which are also in the medical imaging technology space, Aclarion's revenue is significantly lower, indicating a slower market adoption or a different stage of development.
- The company's need to raise additional capital is consistent with the industry, where significant investment is required for research, development, and regulatory approvals.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Bylaws | Amendment to Bylaws dated June 12, 2024 | 2024-06-12 | NA |
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential delisting from Nasdaq.
- Employees may be impacted by potential cost-cutting measures or restructuring due to the company's financial challenges.
- Customers may experience uncertainty regarding the company's ability to continue providing services.
- Creditors face increased risk due to the company's financial difficulties and going concern warning.
Next Steps
- The company intends to monitor the closing bid price of its common stock and is considering its options to regain compliance with the Bid Price Requirement.
- The company plans to secure additional funding to continue technology development.
- The company will continue to work with an outside firm to establish best practices to improve internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2022-04-21 | The company's 2022 Aclarion Equity Incentive Plan went into effect. |
| 2023-01-01 | Start of the period for share information reflecting the reverse stock split. |
| 2023-02-01 | Jeffrey Thramann became the company's Executive Chairman. |
| 2023-02-16 | The company sold one share of Series A preferred stock to Jeffrey Thramann. |
| 2023-03-03 | The company received a notice from Nasdaq for not meeting the minimum stockholders equity requirement. |
| 2023-03-24 | Stockholders approved a reverse stock split proposal. |
| 2023-03-28 | The company redeemed the one outstanding share of Series A preferred stock. |
| 2023-05-01 | Start date of the Senior Notes Payable. |
| 2023-05-16 | Maturity date of the Senior Notes Payable. |
| 2023-09-01 | Start date of the Series B Notes Payable. |
| 2023-09-30 | Maturity date of the Series B Notes Payable. |
| 2023-10-09 | The company entered into an equity line agreement with White Lion Capital. |
| 2023-11-01 | Start date of the Series C Notes Payable. |
| 2023-11-21 | The company issued unsecured senior notes with a maturity date of April 19, 2024. |
| 2023-11-30 | Maturity date of the Series C Notes Payable. |
| 2024-01-01 | Start of the period for the 2024 Stock Split. |
| 2024-01-03 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation. |
| 2024-01-04 | Common stock began trading on a reverse split-adjusted basis on the NASDAQ. |
| 2024-01-22 | Start date of the Exchange Agreements with accredited investors. |
| 2024-01-29 | End date of the Exchange Agreements with accredited investors. |
| 2024-02-27 | The company completed a public offering of 5,175,000 units. |
| 2024-03-06 | The company paid $300,974 of principal and accrued interest on certain unsecured non-convertible notes. |
| 2024-04-08 | The company received a notice from Nasdaq for not meeting the minimum bid price requirement. |
| 2024-04-26 | The company issued 1,050,000 newly issued common shares to White Lion for proceeds of $304,500. |
| 2024-06-30 | End of the reporting period for the quarterly report. |
| 2024-08-12 | The company entered into a subscription agreement with an institutional investor. |
| 2024-08-14 | The company entered into an additional exchange agreement with the accredited investors. |
Keywords
Aclarion, NOCISCAN, financial results, net loss, revenue, operating expenses, debt, public offering, equity line, reverse stock split, Nasdaq, going concern, internal controls
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.